The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
News|Articles|January 1, 2003
- Pharmaceutical Technology-01-01-2003
- Volume 27
- Issue 1
Technical Considerations for the Validation of Electronic Spreadsheets for Complying with 21 CFR Part 11
Author(s)Tuan T. Phan
Bridging the gap between compliant spreadsheet production and limitations in available technology can be achieved by the use of custom-created electronic solutions.
Advertisement
Articles in this issue
over 23 years ago
Pharmaceutical Pricing and Innovation Key Issues for 2003over 23 years ago
Procedures: Improving Their Qualityover 23 years ago
Drug-Carrier Screening on a Chipover 23 years ago
Outsourcing Outlookover 23 years ago
Pack EXPO International 2002 Proves Worth the Tripover 23 years ago
Analysis of the Indian Pharmaceutical IndustryAdvertisement
Related to this article
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, detailed an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement